logo
[breadcrumb_custom]

Tag: NASDAQ: MNPR

Stock Investing

What Drove Monopar Therapeutics (MNPR) Stock Up Nearly 9% After-Hours?

After-hours trading on Monday saw shares of Monopar Therapeutics Inc. (NASDAQ: MNPR) rise 8.78% to $2.23 following the release of encouraging clinical-trial data. What data has MNPR provided? Yesterday, Monopar Therapeutics (MNPR) published encouraging findings with MNPR-202 from its ongoing partnership with the National University of Singapore’s Cancer Science Institute of Singapore (CSI Singapore) (NUS). Next Weekend at the 64th American Society of Hematology (ASH) Plenary Session & Exposition, NUS and Monopar Therapeutics will present a poster with the results (ASH 2022). The poster is accessible on Monopar’s website. A potential DNA Damaging Response (DDR) medication candidate and doxorubicin analog